Jounce Therapeutics, Inc.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focused on developing therapies that enable the immune system to attack tumors. Its lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. The company is also developing JTX-4014, an anti-PD-1 antibody. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts. The science underlying Jounce Therapeutics lead drug candidate JTX-2011 is from the laboratory of Dr. James Alison (Department Chair MD Anderson Cancer Center), a pioneer and world renowned leader in the field of cancer immunotherapy. Dr. Alison recently presented data supporting the clinical development of JTX-2011 during a packed plenary session at the AACR annual oncology meeting, a gathering for top oncology researchers from institutions around the world.

Foresite Capital first invested in Jounce during a private financing in 2015 and again during an initial public offering in early 2017. In addition to a promising pipeline focused on novel cancer targets, Jounce has brought in substantial non-dilutive financing from a deal with Celgene, which included $225M in upfront payments and potential milestones totaling $2.6B.